Bromonitrite oxide can be generated homogeneously in water at acidic pH, allowing efficient [3 + 2] cycloaddition with water soluble olefins and acetylenes. Allylammonium salts react with high regioselectivity and without the need for N-group protection.
Novel rhodesaininhibitors were developed by combining an enantiomerically pure 3-bromoisoxazolinewarhead with a 1,4-benzodiazepine scaffold as specific recognition moiety. All compounds were proven to inhibitrhodesain with Ki values in the low-micromolar range. Their activity towards rhodesain was found to be coupled to an in vitro antitrypanosomal activity, with IC50 values ranging from the mid-micromolar
Bromonitrite oxide can be generated homogeneously in water at acidic pH, allowing efficient [3 + 2] cycloaddition with water soluble olefins and acetylenes. Allylammonium salts react with high regioselectivity and without the need for N-group protection.
Structure−Activity Relationship Analysis of the Selective Inhibition of Transglutaminase 2 by Dihydroisoxazoles
作者:R. Edward Watts、Mathew Siegel、Chaitan Khosla
DOI:10.1021/jm060839a
日期:2006.12.1
Human transglutaminase 2 (TG2) is believed to play an important role in the pathogenesis of various human disorders including celiac sprue, certain neurological diseases, and some types of cancer. Selective inhibition of TG2 should therefore enable further investigation of its role in physiology and disease and may lead to effective clinical treatment. Recently we showed that certain 3-halo-4-,5-dihydroisoxazole containing compounds are selective inhibitors of human TG2 with promising pharmacological activities. Here, we present definitive evidence that this class of compounds targets the active site of human TG2. Structure-activity relationship studies have provided insights into the structural prerequisites for selectivity and have led to the discovery of an inhibitor with about 50-fold higher activity than a prototypical dihydroisoxazole inhibitor with good in vivo activity. A method for preparing enantiomerically enriched analogues was also developed. Our studies show that the 5-(S)-dihydroisoxazole is a markedly better inhibitor of human TG2 than its 5-(R) stereoisomer.
Development of Rhodesain Inhibitors with a 3-Bromoisoxazoline Warhead
作者:Roberta Ettari、Lucia Tamborini、Ilenia C. Angelo、Silvana Grasso、Tanja Schirmeister、Leonardo Lo Presti、Carlo De Micheli、Andrea Pinto、Paola Conti
DOI:10.1002/cmdc.201300390
日期:2013.12
Novel rhodesaininhibitors were obtained by combining an enantiomerically pure 3‐bromoisoxazoline warhead with a specific peptidomimetic recognition moiety. All derivatives behaved as inhibitors of rhodesain, with low micromolar Ki values. Their activity against the enzyme was found to be paralleled by an in vitro antitrypanosomal activity, with IC50 values in the mid‐micromolar range. Notably, a preference